retatrutide type 2 diabetes phase 2 trial Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 ESC 2024: Retatrutide improves lipid

There is local legislation and supply chain concerns

Retrieved from Federal Register

The Emergence of GLP-1 Agonists Building upon the natural roles of GLP-1, researchers developed GLP-1 agonists, which are drugs designed to mimic the effects of the native hormone, consequently fostering a conducive environment for weight loss

Along with protein intake, strength training is the most effective way to preserve lean muscle mass while losing weight

Careful consideration is needed when providing additional regular insulin doses in patients who are already receiving intermediate-acting insulin

Participants with class III obesity (BMI 40 or higher) were more likely to be late responders, meaning they needed more time to achieve significant weight loss